Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05860972 · ClinicalTrials.gov registry record · NA
Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency
A NA study of Hyperhidrosis Primary Focal Axilla, sponsored by InMode MD.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT05860972: Recruiting NA study of Hyperhidrosis Primary Focal Axilla, sponsored by InMode MD.
NCT05860972 is a NA study of Hyperhidrosis Primary Focal Axilla that is actively recruiting participants, run by InMode MD. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05860972, a NA study of Hyperhidrosis Primary Focal Axilla, is actively recruiting participants, sponsored by InMode MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae
Conditions Studied
Interventions
- DEVICE Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
Study Locations (4)
New York
- Skinfluence - New York
Tennessee
- Southeastern Dermatology - Knoxville
Texas
- Dallas Plastic Surgery Institute - Dallas
Other
- RAMBAM Medical Center - Haifa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2026-04 |
| Phase | NA |
What NCT05860972 shows while recruiting
NCT05860972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Hyperhidrosis Primary Focal Axilla appearing as the primary indexed condition, and to 1 intervention - of which Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis. is the first listed.
NCT05860972 reports a single indexed study location in New York, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT05860972 about?
NCT05860972 is a clinical study titled "Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency". The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae
What is the current status of trial NCT05860972?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2023-03-09. Estimated completion is 2026-04.
What conditions does trial NCT05860972 study?
This clinical trial studies the following conditions: Hyperhidrosis Primary Focal Axilla.
What interventions are being tested in trial NCT05860972?
The interventions under investigation include: Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis. (DEVICE).
Who is sponsoring clinical trial NCT05860972?
This trial is sponsored by InMode MD, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05860972 being conducted?
This trial has 4 study locations across New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05860972's enrollment target sits among peer trials
70 1104th of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI